Current Report Filing (8-k)
May 08 2019 - 7:36AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 8, 2019
Intra-Cellular Therapies, Inc.
(Exact name of registrant as specified in its charter)
Commission
File Number: 001-36274
|
|
|
Delaware
|
|
36-4742850
|
(State or other jurisdiction
of incorporation)
|
|
(IRS Employer
Identification No.)
|
430 East 29
th
Street
New York, New York 10016
(Address of principal executive offices, including zip code)
(646) 440-9333
(Registrants telephone number, including area code)
Not applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock
|
|
ITCI
|
|
The Nasdaq Global Select Market
|
ITEM 2.02
|
Results of Operations and Financial Condition.
|
On May 8, 2019, Intra-Cellular Therapies, Inc. (the Company) announced its financial results for the first quarter ended March 31, 2019, and
provided a corporate update.
A copy of the Companys press release containing such announcements is attached hereto as Exhibit 99.1. The information
in the press release set forth in the first four paragraphs under the heading Selected First Quarter 2019 Financial Results, together with the condensed consolidated financial information included in the press release, are incorporated
by reference into this Item 2.02 of this Current Report on Form 8-K.
In the press release dated May 8, 2019, the Company also provided a corporate update. The information set forth in the last paragraph under the heading
Selected First Quarter 2019 Financial Results and under the headings Corporate Update and About Intra-Cellular Therapies, together with the forward-looking statement disclaimer at the end of the press release, are
incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.
ITEM 9.01
|
Financial Statements and Exhibits.
|
The press release may contain hypertext links to information on our website. The information on our website is not
incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K.
The portions of the press release
incorporated by reference into Item 8.01 of this Current Report on Form 8-K are being filed pursuant to Item 8.01. The remaining portions of the press release are being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not
be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
INTRA-CELLULAR THERAPIES, INC.
|
|
|
By:
|
|
/s/ Lawrence J. Hineline
|
|
|
Lawrence J. Hineline
|
|
|
Senior Vice President of Finance, Chief Financial Officer, Treasurer
and Assistant Secretary
|
Date: May 8, 2019
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Apr 2023 to Apr 2024